Significant clinical progress of global new tumor drugs
Lung Cancer 1.Tilelizumab’s second-line or third-line treatment of non-small cell lung cancer Phase III RATIONALE 303 trial reached its primary clinical endpoint. On November 17, BeiGene announced the interim analysis […]
Read More →